Safety and effectiveness of the sodium‐glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus

BACKGROUND: Bexagliflozin is a sodium‐glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM). OBJECTIVE: To evaluate the safety and effectiveness of bexagliflozin as a monotherapy for DM i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadd, Michael J., Bienhoff, Stephen E., Little, Susan E., Geller, Samuel, Ogne‐Stevenson, Jennifer, Dupree, Thomas J., Scott‐Moncrieff, J. Catharine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229323/
https://www.ncbi.nlm.nih.gov/pubmed/37148170
http://dx.doi.org/10.1111/jvim.16730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229323/
https://www.ncbi.nlm.nih.gov/pubmed/37148170
http://dx.doi.org/10.1111/jvim.16730

Ejemplares similares